Plasma C-reactive protein levels are associated with improved outcome in ARDS

Chest

Volumn 136, Issue 2, 2009, Pages 471-480

  Bajwa, Ednan K ^a   Khan, Uzma A ^b   Januzzi, James L ^a   Gong, Michelle N ^c   Thompson, B Taylor ^a   Christiani, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; STEROID THERAPY; SURVIVAL; SURVIVOR;

EID: 68849093117     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2413     Document Type: Article

References (46)

1. Wood HF, McCarty CM, Slater RJ. The occurrence during acute infections of a protein not normally present in the blood: V; physical-chemical properties of the C-reactive protein crystallized by a modified technique. J Exp Med 1954; 100:71-79
2. Okamura JM, Miyagi JM, Terada K, et al. Potential clinical applications of C-reactive protein. J Clin Lab Anal 1990; 4:231-235
3. Blackburn WD Jr. Validity of acute phase proteins as markers of disease activity. J Rheumatol Suppl 1994; 42:9-13
4. Castelli GP, Pognani C, Cita M, et al. Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 2006; 72:69-80
5. Chung JL, Kong MS, Lin SL, et al. Diagnostic value of C-reactive protein in children with perforated appendicitis. Eur J Pediatr 1996; 155:529-531
6. Holm A, Pedersen SS, Nexoe J, et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57:555-560
7. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65(suppl):S253-S259
8. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27:337-349
9. Liu KD, Glidden DV, Eisner MD, et al. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med 2007; 35:2755-2761
10. McClintock DE, Ware LB, Eisner MD, et al. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2007; 175:256-262
11. Parsons PE, Matthay MA, Ware LB, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288:L426-L431
12. Abernathy VJ, Webster RO, Dahms TE. C-reactive protein inhibits increased pulmonary vascular permeability induced by fMLP in isolated rabbit lungs. Am J Physiol 1996; 271: H507-H513
13. Grad E, Golomb M, Mor-Yosef I, et al. Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am J Physiol Heart Circ Physiol 2007; 293:H489-H495
14. Heuertz RM, Ahmed N, Webster RO. Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J Immunol 1996; 156:3412-3417
15. Heuertz RM, Piquette CA, Webster RO. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol 1993; 142:319-328
16. Heuertz RM, Xia D, Samols D, et al. Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am J Physiol 1994; 266:L649-L654
17. Hyers TM, Kew RR, Krsek-Staples J, et al. Regulation of neutrophil function by acute phase reactants: implications for resolution of the adult respiratory distress syndrome. Chest 1991; 99(suppl):S7-S9
18. Gong MN, Wei Z, Xu LL, et al. Polymorphism in the surfactant protein-B gene, gender, and the risk of direct pulmonary injury and ARDS. Chest 2004; 125:203-211
19. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-824
20. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-1636
21. Bernard GR, Doig G, Hudson L. Quantification of organ failure for clinical trials and clinical practice [abstract]. Am J Respir Crit Care Med 1995; 151:A323
22. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-35
23. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000; 19:1793-1819
24. Schmidt SC, Hamann S, Langrehr JM, et al. Preoperative high-dose steroid administration attenuates the surgical stress response following liver resection: results of a prospective randomized study. J Hepatobiliary Pancreat Surg 2007; 14: 484-492
25. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007; 16:14-21
26. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565
27. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397
28. Lee CC, Chen SY, Tsai CL, et al. Prognostic value of mortality in emergency department sepsis score, procalcitonin, and C-reactive protein in patients with sepsis at the emergency department. Shock 2008; 29:322-327
29. Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003; 123:2043-2049
30. Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005; 33:792-796
31. Pettila V, Hynninen M, Takkunen O, et al. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002; 28:1220-1225
32. Ugarte H, Silva E, Mercan D, et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999; 27:498-504
33. Philip AG. The protective effect of acute phase reactants in neonatal sepsis. Acta Paediatr Scand 1979; 68:481-483
34. Peltola H, Jaakkola M. Serious bacterial infections: C-reactive protein as a serial index of severity. Clin Pediatr 1988; 27:532-537
35. Presterl E, Staudinger T, Pettermann M, et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997; 156:825-832
36. Powe JE, Short A, Sibbald WJ, et al. Pulmonary accumulation of polymorphonuclear leukocytes in the adult respiratory distress syndrome. Crit Care Med 1982; 10:712-718
37. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005; 288:L3-L15
38. Moraes TJ, Zurawska JH, Downey GP. Neutrophil granule contents in the pathogenesis of lung injury. Curr Opin Hematol 2006; 13:21-27
39. Martin TR, Nakamura M, Matute-Bello G. The role of apoptosis in acute lung injury. Crit Care Med 2003; 31(suppl): S184-S188
40. Buchta R, Fridkin M, Pontet M, et al. Modulation of human neutrophil function by C-reactive protein. Eur J Biochem 1987; 163:141-146
41. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528-1536
42. Heuertz RM, Tricomi SM, Ezekiel UR, et al. C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement. J Biol Chem 1999; 274:17968-17974
43. Zhong W, Zen Q, Tebo J, et al. Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. J Immunol 1998; 161:2533-2540
44. Dobrinich R, Spagnuolo PJ. Binding of C-reactive protein to human neutrophils: inhibition of respiratory burst activity. Arthritis Rheum 1991; 34:1031-1038
45. Li JJ, Sanders RL, McAdam KP, et al. Impact of C-reactive protein (CRP) on surfactant function. J Trauma 1989; 29: 1690-1697
46. Rice TW, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: challenges in clinical trial design. Clin Chest Med 2006; 27:733-754